Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT02500381 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: SRP-4045
DRUG: SRP-4053
DRUG: Placebo

Sponsor

Sarepta Therapeutics, Inc.